Rothschild & Co Downgrades Medpace Hldgs to Neutral, Raises Price Target to $474

Benzinga · 09/03/2025 15:19
Rothschild & Co analyst Jamie Clark downgrades Medpace Hldgs (NASDAQ:MEDP) from Buy to Neutral and raises the price target from $342 to $474.